• Life Sciences & Health
  • Invest
  • Exits

NOM sells Polyganics to CMI

Groningen-based Polyganics, a producer of innovative biodegradable medical products, becomes part of Oakland, US-based Collagen Matrix Inc. (CMI). CMI has acquired 100% of the shares of Polyganics. NOM had been involved with Polyganics since 2000, which now has 75 employees.

Polyganics originated as a spin-out from the University of Groningen in 1999 and has since developed and brought to market several innovative products based on its proprietary polymer platform technology. The unique bioresorbable products focus on tissue repair after surgery.

Ready for next step

"We are very proud of Polyganics and what the team has accomplished since its inception in 1999," said Annemieke Wouterse and Ytsen van der Meer, investment managers at NOM. "The company is ready for the next phase. We expect that with the broad knowledge base, the already developed products and the state-of-the-art production facility on the Zernike Campus, Polyganics will have a bright future under the wings of CMI. Polyganics' success is based on its experienced, knowledgeable and dedicated team of employees and strong collaboration with key opinion leaders in the various markets."

Also positive for the region

Rudy Mareel, CEO of Polyganics, said, "This transaction is an excellent next step in the further development of Polyganics. It provides the company with additional resources to further expand both research and manufacturing capabilities and accelerate the introduction of breakthrough products to the market. I am incredibly proud of the team we have been able to assemble under the Polyganics banner to build on the groundbreaking technology of biocompatible and bioresorbable polymers. Not only the employees of Polyganics will reap the benefits of the coming together of the two companies, but also the Groningen region and in particular the Zernike Campus, which has gained an even stronger innovative company as a result of this transaction."